Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 250Carcinoma, Renal Cell 89Urinary Bladder Neoplasms 67Breast Neoplasms 41Carcinoma, Transitional Cell 37Colorectal Neoplasms 33Ovarian Neoplasms 32Melanoma 31Carcinoma, Non-Small-Cell Lung 31Kidney Neoplasms 30Neoplasms 28Neoplasm Metastasis 26Sarcoma 25Uterine Cervical Neoplasms 20Lung Neoplasms 20Endometrial Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 19Wilms Tumor 17Adenocarcinoma 17Stomach Neoplasms 16Pancreatic Neoplasms 16Carcinoma, Hepatocellular 16Triple Negative Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Metastatic Castration-resistant Prostate Cancer 13Esophageal Neoplasms 13Rhabdomyosarcoma 12Osteosarcoma 12Neuroblastoma 12Head and Neck Neoplasms 12

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castrate Sensitive Prostate Cancer × Genitourinary × 30 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡